The stock's fall snapped a two-day winning streak.

The company also offers platform-agnostic next-generation sequencing tests and a suite of sample prep and thermal cycling instruments.

A promising new COVID-19 vaccine candidate developed by researchers at the Centenary Institute and the University of Sydney ...

A research team with Professor Neha Kamat used synthetic liposomes and bacterial extracts to generate immune responses ...

The collaboration will utilise DXC's advanced AI capabilities to improve automation, agility, and customer interactions.

DXC Technology Co. closed 42.37% below its 52-week high of $24.83, which the company reached on November 8th.